EUCTR2013-000311-25-BE进行中（未招募）不适用
A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC) - Refametinib in RAS mutant HCC
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligibility criteria for RAS mutation testing:
- •Ability to understand and willingness to sign written informed consent (IC). Signed informed consent from (ICF) for RAS mutation testing has to be obtained before any study specific procedure.
- •Unresectable or metastatic HCC, confirmed either by histology or clinically according to the American Association for the Study of Liver Disease (AASLD) criteria for cirrhotic patients. For non-cirrhotic patients, histological confirmation is mandatory.
- •Male or female =18 years of age.
- •ECOG performance state 0 or 1.
- •Life expectancy of at least 12 weeks.
- •No prior use of targeted agents, experimental therapy or systemic anti-cancer treatment for HCC (except sorafenib) (changed by Amendment 1, only sorafenib allowed as prior systemic anticancer therapy).
- •No previous treatment with refametinib.
- •Criteria for study treatment eligibility:
- •Ability to understand and willingness to sign written IC. Signed ICF for study treatment eligibility has to be obtained before any study specific procedure.
- •Patient must harbor KRAS or NRAS mutation based on BEAMing plasma test.
- •Patients must have at least one uni-dimensional measurable lesion by CT or MR according to RECIST 1.1 and mRECIST (specified in Section 14.4) which is either naïve (not previously treated by local therapy such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) or previously treated and has progressed until baseline (both, measureable lesion and/or progressed lesion have to be confirmed by central image review of baseline and progression scan).
- •Patients who have received local therapy such as surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation are eligible. Previously treated lesions are only selected as target lesions when they have progressed (to be confirmed by central image review of an initial set of scans taken after the local treatment and another showing progression. At least 8 weeks are needed between the scans). Local therapy has to be completed at least 4 weeks prior to the baseline scan.
- •Resolution of all acute toxic effects of any prior local therapy to Common Toxicity Criteria for Adverse Events (CTCAE 4.03) grade =1.
- •ECOG performance status of 0 or 1.
- •Liver function status of Child-Pugh Class A.
- •The following laboratory criteria must be met:
- •Platelet count = 60 x 109/L
- •Hemoglobin = 8.5 g/dL
- •Absolute neutrophil count (ANC) = 1.5 x 109/L
- •Total bilirubin = 3.0 mg/dL
- •Alanine aminotransferase (ALT) = 5 x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) = 5 x ULN
- •Albumin = 2.8 g/dL
- •Amylase and lipase = 1.5 x ULN
- •Serum creatinine = 1.5 x ULN
- •Prothrombin time-international normalized ratio (PT-INR) =2.3, or PT = 6 seconds above control.
- •Patient has within normal range cardiac function confirmed by the enrolling clinical institute as measured by echocardiogram or multiple gated acquisition (MUGA) scan.
- •Patients who are therapeutically anti-coagulated with an agent such as warfarin or heparin are allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until INR is stable (within Child Pugh class A threshold) based on a measurement at pre-dose, as defined by the local standard
排除标准
- •Any Cancer curatively treated < 3 years prior to study entry, except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Staging: Ta, Tis and T1).
- •Patients who are eligible for surgery, liver transplantation, ablation or transarterial chemoembolization for HCC.
- •Renal failure requiring hemo- or peritoneal dialysis.
- •History of cardiac disease
- •-Congestive heart failure New York Heart Association (NYHA) > class 2.
- •-Unstable angina (angina symptoms at rest, new-onset angina i.e. within the last 3 months) or myocardial infarction (MI) within the past 6 months prior to start of screening.
- •-Cardiac arrhythmias requiring anti-arrhythmic therapy.
- •Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg or diastolic blood pressure > 90 mmHg despite optimal medical management).
- •Ongoing infection > Grade 2 according to NCI-CTCAE version 4.0. Hepatitis B is allowed if no active replication (defined as abnormal ALT >2xULN associated with HBV DNA >20,000 IU/mL ) is present (45). Hepatitis C is allowed if no antiviral treatment is required.
- •Known human immunodeficiency virus (HIV) infection.
- •Known history of, or symptomatic metastatic brain or meningeal tumors (head CT or MR at Screening to confirm the absence of central nervous system [CNS] disease if patient had symptoms suggestive or consistent with CNS disease).
- •History of interstitial lung disease (ILD).
- •History of hepatic encephalopathy.
- •Clinically significant GI bleeding (CTCAE 4.03 grade 3 or higher) within 30 days prior to start of screening.
- •Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months prior to start of screening.
- •History of organ allograft, cornea transplantation will be allowed.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.
- •Known or suspected hypersensitivity to any of the study drugs, study drug classes, or components in the formulation given during the course of this study.
- •Patients unable to take oral medication, requiring intravenous alimentation, who had malabsorption syndrome or any other conditions affecting GI absorption, or who have active peptic ulcer disease.
- •Any condition that was unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
- •Pregnant or lactating women.
- •Uncontrolled ascites (defined as not easily controlled with diuretic treatment).
- •History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
- •Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.
- •Non-healing wound, ulcer, or bone fracture.
- •Patients with large esophageal varices at risk of bleeding that are not being treated with conventional medical intervention: beta blockers or endoscopic treatment. Assessment of esophageal varices should be performed by endoscopy within 6 months prior to start of study treatment and within 12 months for patients in whom conventional medical intervention for known esophageal varices is already in place.
- •Patients with seizure disorder requiring medication.
- •Excluded previous therapies and medications:
- •Radiotherapy within 4 weeks prior to start of screening. Patients must have recovered from all therapy-related toxicities. The site of previous radiotherapy should have evi
研究者
相似试验
进行中（未招募）
不适用
Refametinib given to patients with unresectable or metastatic HCC carrying a RAS mutatioKRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)EUCTR2013-000311-25-FRBayer Healthcare AG2,650
进行中（未招募）
1 期
Refametinib given in combination with sorafenib to patients with advanced HCC carrying a RAS mutatioKRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)EUCTR2013-000241-39-DEBayer HealthCare AG2,650
进行中（未招募）
不适用
Refametinib given to patients with unresectable or metastatic HCC carrying a RAS mutatioKRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)EUCTR2013-000311-25-CZBayer Healthcare AG2,650
进行中（未招募）
1 期
Refametinib given in combination with sorafenib to patients with advanced HCC carrying a RAS mutatioKRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)EUCTR2013-000241-39-ATBayer HealthCare AG2,650
进行中（未招募）
不适用
Refametinib given to patients with unresectable or metastatic HCC carrying a RAS mutatioKRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)EUCTR2013-000311-25-HUBayer Healthcare AG2,650